CURB-65 plus hypoalbuminemia: a new score system for prediction of the in-hospital mortality risk in patients with SARS-CoV-2 pneumonia.
CALL score
CRP
CURB-65
ICU admission
PSI score
extended CURB-65
hypoalbuminemia
mortality
Journal
Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
06
2021
accepted:
27
07
2021
entrez:
11
2
2022
pubmed:
12
2
2022
medline:
12
2
2022
Statut:
epublish
Résumé
There is the need of a simple but highly reliable score system for stratifying the risk of mortality and Intensive Care Unit (ICU) transfer in patients with SARS-CoV-2 pneumonia at the Emergency Room. In this study, the ability of CURB-65, extended CURB-65, PSI and CALL scores and C-Reactive Protein (CRP) to predict intra-hospital mortality and ICU admission in patients with SARS-CoV-2 pneumonia were evaluated. During March-May 2020, a retrospective, single-center study including all consecutive adult patients with diagnosis of SARS-CoV-2 pneumonia was conducted. Clinical, laboratory and radiological data as well as CURB-65, expanded CURB-65, PSI and CALL scores were calculated based on data recorded at hospital admission. Overall, 224 patients with documented SARS-CoV-2 pneumonia were included in the study. As for intrahospital mortality (24/224, 11%), PSI performed better than all the other tested scores, which showed lower AUC values (AUC=0.890 for PSI The addition of albumin level to the easy-to-calculate CURB-65 score at hospital admission is able to improve the quality of prediction of intra-hospital mortality in patients with SARS-CoV-2 pneumonia.
Identifiants
pubmed: 35146346
doi: 10.53854/liim-2903-12
pii: 1124-9390_29_3_2021_408-415
pmc: PMC8805501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
408-415Informations de copyright
Copyright © 2016 - 2021 InfezMed.
Déclaration de conflit d'intérêts
Competing interests The authors declare no financial and non-financial competing interests.
Références
Thorax. 2003 May;58(5):377-82
pubmed: 12728155
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Lancet. 2020 Mar 28;395(10229):1014-1015
pubmed: 32197108
J Crit Care. 2011 Jun;26(3):287-94
pubmed: 21129911
J Infect Chemother. 2018 Aug;24(8):602-609
pubmed: 29628384
Clin Chim Acta. 2009 May;403(1-2):23-30
pubmed: 19141296
J Med Virol. 2021 May;93(5):2611-2613
pubmed: 33554335
Antioxid Redox Signal. 2021 Jul 10;35(2):139-142
pubmed: 32524832
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Sci Rep. 2016 Mar 18;6:22911
pubmed: 26987602
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nat Rev Cancer. 2018 Oct;18(10):619-633
pubmed: 30097614
Respir Care. 2018 Jan;63(1):43-49
pubmed: 29066584
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
N Engl J Med. 1997 Jan 23;336(4):243-50
pubmed: 8995086
Ann Intensive Care. 2013 Feb 15;3(1):4
pubmed: 23414610
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Infect. 2013 May;66(5):415-23
pubmed: 23286966
Infez Med. 2020 Dec 1;28(4):534-538
pubmed: 33257627
Open Forum Infect Dis. 2018 Nov 17;5(11):ofy291
pubmed: 30515432
Med Hypotheses. 2020 Apr 24;140:109790
pubmed: 32353740
Hepatol Commun. 2020 Jul 21;:
pubmed: 32838104
Circ Res. 2020 Jul 17;127(3):400-401
pubmed: 32508261
Int J Antimicrob Agents. 2020 May;55(5):105951
pubmed: 32234466
Expert Rev Clin Pharmacol. 2018 Feb;11(2):125-137
pubmed: 29219627
J Infect. 2020 Aug;81(2):282-288
pubmed: 32479771
BMJ. 2020 Feb 28;368:m810
pubmed: 32111649
EBioMedicine. 2020 Jul;57:102880
pubmed: 32645614
Crit Care. 2020 Jul 2;24(1):389
pubmed: 32616077